NeoGenomics (NEO) and Immunogen (IMGN) Launch Ovarian Cancer Patient Access Program for FR Biomarker Testing to Support Launch of ELAHERE


News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.


NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of global oncology testing and contract research services, today launched a new biomarker testing program for patients with epithelial ovarian cancer, including primary ovarian cancers. peritoneum or fallopian tubes (COE). Through the FR-ASSIST™ program, sponsored by ImmunoGen, Inc., (Nasdaq: IMGN), EOC patients will have access to the FOLR1 IHC CDx assay (VENTANA FOLR1 RxDx Assay) performed by NeoGenomics to measure the expression of a protein called folate receptor alpha (FRα).

The FR-ASSIST™ program was launched in conjunction with the recent U.S. Food and Drug Administration approval of ELAHERE™ (mirvetuximab soravtansine-gynx), ImmunoGen’s antibody-drug conjugate (ADC) targeting FRα in patients with platinum-resistant ECC.

The new testing program is fully sponsored by ImmunoGen and provides eligible EOC patients with FRα expression testing through NeoGenomics at no cost, regardless of insurance coverage or test results.

“We are delighted to partner with ImmunoGen on this first-of-its-kind testing program. Together, we are combining our leadership in biomarker testing with ImmunoGen’s expertise in developing new targeted therapies to address a critically important unmet need in ovarian cancer. “, said Shashikant Kulkarni, MS (medicine), PhD, scientific director of NeoGenomics.

FRα is rarely expressed in normal tissues, but is often elevated in solid cancerous tumors, including EOCs. Of the approximately 19,880 ovarian cancers diagnosed in 2022,[1] nearly 90% of these cases would be expected to express FRα,[2],[3],[4]representing an attractive target for cancer therapy.

“Biomarker testing is an integral part of personalized medicine, especially for patients with ovarian cancer, as it can help oncologists and their patients make more informed decisions about treatment approaches,” said said Derek Lyle, MD, medical director of NeoGenomics. “Sponsored programs like FR-ASSIST™ are an innovative and effective way to ensure patients get the right test to help them receive the right treatment at the right time, especially innovative targeted therapies that have been shown to ‘they improve patient outcomes.”

“With the approval of ImmunoGen’s ELAHERE™ – the first and only FRα-targeting ADC for platinum-resistant ovarian cancer – it is more important than ever that all patients with EOC be tested for the expression of FRα,” said Mark Enyedy, President and CEO, ImmunoGen. “Despite the vital information provided by biomarker testing, many cancer patients still do not undergo evaluation due to a lack of awareness, access and reimbursement. By partnering with a leader in the ‘Innovation like NeoGenomics, our FR-ASSIST™ program helps break down these barriers so that all EOC patients have access to the FOLR1 IHC test, regardless of insurance coverage.”

All patients with COE may be eligible to participate in ImmunoGen’s FR-ASSIST™ testing program. For more information, including full program terms and conditions, please visit: https://neogenomics.com/diagnostic-services/sponsored-testing-programs/folr1-ovarian-cancer-testing-program.

ELAHERE™ (mirvetuximab soravtansine-gynx) is a trademark of ImmunoGen, Inc. For more information, including important safety information, please visit https://investor.immunogen.com/news-releases/news-release-details/immunogen-announces-fda-accelerated-approval-elaheretm

About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in cancer genetic testing and information services, offering one of the world’s most comprehensive oncology-focused test menus for physicians to help diagnose and treat cancer. The Company’s Pharmaceutical Services division serves pharmaceutical clients in clinical trials and drug development.

NeoGenomics is committed to connecting patients with life-changing therapies and trials. We believe that together, with our partners, we can help cancer patients today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to all applicable data protection laws, provides transparency and choice to patients regarding the processing and use of their data through our Notice of Privacy Practicesand has invested in state-of-the-art technology to ensure that the data we retain is secure at all times.

Based in Fort Myers, Florida, NeoGenomics operates CAP-accredited and CLIA-certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; Houston, TX; Atlanta, Georgia; Nashville, TN; and CAP accredited laboratories in Rolle, Switzerland; and Singapore and China. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical companies, integrated service delivery networks and managed care organizations in the United States, as well as pharmaceutical companies in Europe and Asia .

About ImmunoGen

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerance profiles, we aim to disrupt cancer progression and provide our patients with more good days. We call it our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do and how we do it at www.immunogen.com.

Forward-looking statements

This press release contains forward-looking statements. These forward-looking statements can generally be identified by the use of words such as “anticipate”, “expect”, “plan”, “could”, “could”, “could”, “will”, “believe”, “estimate”, “forecast”, “goal”, “project”, “direction”, “plan”, “potential” and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements address a variety of topics, including statements regarding improved operating efficiencies, return to profitable growth and its ongoing executive search process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by Applicable risks and uncertainties include, among others, the Company’s ability to identify and implement appropriate financial and operational initiatives to improve performance, identify and recruit leadership candidates, continue to win new customers, respond to the effects of the COVID outbreak -19, propose new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading “Risk Factors” in the Company’s Annual Report on Form 10 -K for l year ended December 31, 2021 filed with the SEC on February 25, 2022 together with other information previously filed with the SEC.

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. We encourage you to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements contained in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. . Our business is subject to substantial risks and uncertainties, including those mentioned above. Investors, potential investors and others should pay particular attention to these risks and uncertainties.

For more information, please contact:

NeoGenomics, Inc.
William B. Bonello
Financial director
Tel: 239.768.0600 x2426
[email protected]

[1] SEER Cancer Statistical Facts: Ovarian Cancer. National Cancer Institute. Accessed October 4, 2022.

[2] Markert S, Lassmann S, Gabriel B, et al. Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Anticancer Res. 2008;28(6A):3567-3572.

[3] Parker N, Turk MJ, Westrick E, et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal biochemistry. 2005;338(2):284-293.

[4]Toffoli G, Cernigoi C, Russo A, et al. Overexpression of folate binding protein in ovarian cancers. Int J Cancer. 1997;74(2):193-198.

THE SOURCE: NeoGenomics, Inc.

See the source version on accesswire.com:
https://www.accesswire.com/726985/NeoGenomics-and-ImmunoGen-Launch-New-Program-Giving-Ovarian-Cancer-Patients-Access-to-Novel-FR-Biomarker-Testing-to-Support-the- Launch-ELAHERETM

Ryan H. Bowman